热门资讯> 正文
NeuroBo Pharmaceuticals GAAP每股收益为-1.85美元
2024-08-15 23:57
- NeuroBo Pharmaceuticals press release (NASDAQ:NRBO): Q2 GAAP EPS of -$1.85.
- Cash was approximately $27.9 million as of June 30, 2024, compared to approximately $22.4 million as of December 31, 2023.
-
More on NeuroBo Pharmaceuticals
- NeuroBo Pharmaceuticals signs exclusive license agreement with Mthera Pharma
- NeuroBo Pharma prices private placement and direct offering to raise up to $70M
- Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals
- Historical earnings data for NeuroBo Pharmaceuticals
- Financial information for NeuroBo Pharmaceuticals
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。